Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-26 · 1181 Präparate · 62955 Quellenpassagen · 167 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 21–22
HOS-135674 · Präparat HOS-097762
a
Includes reports of urinary tract infection, cystitis, pyelonephritis, escherichia urinary tract infection,
urinary tract infection bacterial, kidney infection, pyelonephritis acute, pyelonephritis chronic, pyelitis,
renal abscess, streptococcal urinary tract infection, urethritis, urinary tract infection fungal, urinary
tract infection pseudomonal.
b
Includes reports of pneumonia, bronchitis, lower respiratory tract infection, infectious pleural
effusion, tracheobronchitis, atypical pneumonia, lung abscess, infective exacerbation of chronic
obstructive airways disease, paracancerous pneumonia, pyopneumothorax, pleural infection, post
procedural pneumonia.
c
Includes reports of blood creatinine increased, hypercreatininaemia.
d
Includes reports of immune thrombocytopenia (reported in studies outside the pooled dataset),
thrombocytopenia, platelet count decreased.
21
e
Includes reports of neutropenia, neutrophil count decreased, febrile neutropenia, neutropenic sepsis,
granulocytopenia.
f
Includes reports of white blood cell count decreased, leukopenia.
g
Includes reports of lymphopenia, lymphocyte count decreased.
h
Includes reports of infusion-related reaction, cytokine release syndrome, hypersensitivity,
anaphylaxis.
i
Includes reports of anti-thyroid antibody positive, autoimmune hypothyroidism, autoimmune
thyroiditis, blood thyroid stimulating hormone decreased, blood thyroid stimulating hormone
increased, euthyroid sick syndrome, goitre, hypothyroidism, immune-mediated hypothyroidism,
immune-mediated thyroiditis, myxoedema, primary hypothyroidism, thyroid disorder, thyroid
hormones decreased, thyroid function test abnormal, thyroiditis, thyroiditis acute, thyroxine decreased,
thyroxine free decreased, thyroxine free increased, thyroxine increased, tri-iodothyronine decreased,
tri-iodothyronine increased, tri-iodothyronine free abnormal, tri-iodothyronine free decreased, tri-
iodothyronine free increased, silent thyroiditis.
j
Includes reports of hyperthyroidism, Basedow’s disease, endocrine ophthalmopathy, exophthalmos.
k
Includes reports of diabetes mellitus, type 1 diabetes mellitus, diabetic ketoacidosis, ketoacidosis.
l
Includes reports of adrenal insufficiency, blood corticotropin decreased, glucocorticoid deficiency,
primary adrenal insufficiency, secondary adrenocortical insufficiency.
m
Includes reports of hypophysitis, hypopituitarism, secondary adrenocortical insufficiency,
temperature regulation disorder.
n
Includes reports of hypomagnesaemia, blood magnesium decreased.
o
Includes reports of neuropathy peripheral, autoimmune neuropathy, peripheral sensory neuropathy,
polyneuropathy, herpes zoster, peripheral motor neuropathy, neuralgic amyotrophy, peripheral
sensorimotor neuropathy, toxic neuropathy, axonal neuropathy, lumbosacral plexopathy, neuropathic
arthropathy, peripheral nerve infection, neuritis, immune-mediated neuropathy.
p
Includes reports of Guillain-Barré syndrome, ascending flaccid paralysis, demyelinating
polyneuropathy.
q
Includes reports of encephalitis, encephalitis autoimmune, meningitis, meningitis aseptic,
photophobia.
r
Includes reports of myasthenia gravis.
s
Includes reports of myocarditis, autoimmune myocarditis, and immune-mediated myocarditis.
t
Includes reports of pneumonitis, lung infiltration, bronchiolitis, immune-mediated lung disease,
immune-mediated pneumonitis, interstitial lung disease, alveolitis, lung opacity, pulmonary fibrosis,
pulmonary toxicity, radiation pneumonitis.
u
Includes reports of diarrhoea, defaecation urgency, frequent bowel movements, gastrointestinal
hypermotility.
v
Includes reports of colitis, autoimmune colitis, colitis ischaemic, colitis microscopic, colitis
ulcerative, diversion colitis, eosinophilic colitis, immune-mediated enterocolitis.
w
Includes reports of oropharyngeal pain, oropharyngeal discomfort, throat irritation.
x
Includes reports of autoimmune pancreatitis, pancreatitis, pancreatitis acute, lipase increased,
amylase increased.
y
Includes reports of ascites, autoimmune hepatitis, hepatic cytolysis, hepatitis, hepatitis acute,
hepatitis toxic, hepatotoxicity, immune-mediated hepatitis, liver disorder, drug-induced liver injury,
hepatic failure, hepatic steatosis, hepatic lesion, liver injury, oesophageal varices haemorrhage, varices
oesophageal, spontaneous bacterial peritonitis.
z
Includes reports of acne, blister, dermatitis, dermatitis acneiform, dermatitis allergic, drug eruption,
eczema, eczema infected, erythema, erythema of eyelid, eyelid rash, fixed eruption, folliculitis,
furuncle, hand dermatitis, immune-mediated dermatitis, lip blister, oral blood blister, palmar-plantar
erythrodysaesthesia syndrome, pemphigoid, rash, rash erythematous, rash macular, rash maculo-
papular, rash morbilliform, rash papular, rash papulosquamous, rash pruritic, rash pustular, rash
vesicular, scrotal dermatitis, seborrhoeic dermatitis, skin exfoliation, skin toxicity, skin ulcer, vascular
access site rash.
aa
Includes reports of musculoskeletal pain, myalgia, bone pain.
ab
Includes reports of myositis, rhabdomyolysis, polymyalgia rheumatica, dermatomyositis, muscle
abscess, myoglobin urine present, myopathy, polymyositis.
ac
Includes reports of proteinuria, protein urine present, haemoglobinurea, urine abnormality, nephrotic
syndrome, albuminuria.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 0c526c02698fde680b94846dca5e938a75e433412640a491a8eef3004c266563 · Zeichen 8684–14139 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 22–23
HOS-135675 · Präparat HOS-097762
22
ad
Includes reports of nephritis, autoimmune nephritis, Henoch-Schonlein purpura nephritis,
paraneoplastic glomerulonephritis, tubulointerstitial nephritis.
ae
Includes reports of hypokalaemia, blood potassium decreased.
af
Includes reports of hyponatraemia, blood sodium decreased.
ag
Includes reports of hypoxia, oxygen saturation decreased, pO2 decreased.
ah
Includes reports of alopecia, madarosis, alopecia areata, alopecia totalis, hypotrichosis.
ai
Includes reports of hypertension, blood pressure increased, hypertensive crisis, blood pressure
systolic increased, diastolic hypertension, blood pressure inadequately controlled, retinopathy
hypertensive, hypertensive nephropathy, essential hypertension, orthostatic hypertension.
aj
Includes reports of sepsis, septic shock, urosepsis, neutropenic sepsis, pulmonary sepsis, bacterial
sepsis, klebsiella sepsis, abdominal sepsis, candida sepsis, escherichia sepsis, pseudomonal sepsis,
staphylococcal sepsis.
ak
Includes reports of dermatitis bullous, exfoliative rash, erythema multiforme, dermatitis exfoliative,
dermatitis exfoliative generalised, toxic skin eruption, Stevens-Johnson syndrome, drug reaction with
eosinophilia and systemic symptoms, toxic epidermal necrolysis, cutaneous vasculitis.
al
Includes reports of cystitis noninfective and immune-mediated cystitis.
am
Includes reports of nasopharyngitis, nasal congestion and rhinorrhoea.
an
Includes reports of psoriasis, dermatitis psoriasiform.
ao
Includes reports of pericarditis, pericardial effusion, cardiac tamponade and pericarditis constrictive.
ap
Includes reports of dry skin, xerosis.
aq
Includes reports of lichenoid keratosis, lichen sclerosus and lichen planus.
ar
Includes reports of sarcoidosis, pulmonary sarcoidosis, and sarcoidosis of lymph node.
as
Includes reports of uveitis, iridocyclitis and iritis.
at
Includes reports of arthritis, joint swelling, osteoarthritis, rheumatoid arthritis, polyarthritis, spinal
osteoarthritis, autoimmune arthritis, immune-mediated arthritis, spondylitis, joint effusion,
arthropathy, oligoarthritis, rheumatic disorder.
au
Includes reports of tendonitis, tendon pain, tenosynovitis and synovitis.
av
Includes reports of autoimmune haemolytic anaemia, haemolytic anaemia.
aw
Includes reports of anaemia, haemoglobin decreased, and red blood cell count decreased.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage aa50378ac541e7e0e3b9ddde37b9404b53ac51c6747cceaf0b0fcfb40efea12c · Zeichen 14193–16611 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 23
HOS-135676 · Präparat HOS-097762
Description of selected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage f66db2a8100a521c1dea72ff90e696fa3846f9d5fcd6cf8e5e03ce5d71bde4a7 · Zeichen 16613–16654 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 23
HOS-135677 · Präparat HOS-097762
The data below reflect information for significant adverse reactions for atezolizumab as monotherapy
in clinical trials (see section 5.1). Details for the significant adverse reactions for atezolizumab when
given in combination are presented if clinically relevant differences were noted in comparison to
atezolizumab monotherapy. The management guidelines for these adverse reactions are described in
sections 4.2 and 4.4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 22feb842ae16279a39ad2b738cc5dd2193f1934c33160518fd80aa11de9f9f79 · Zeichen 16656–17079 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 23
HOS-135678 · Präparat HOS-097762
Immune-mediated pneumonitis
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 92b9ca5e2f179e04f5d10fbebd5d67a49b8143e8a122a90dfd39948cccab704b · Zeichen 17081–17108 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 23
HOS-135679 · Präparat HOS-097762
Pneumonitis occurred in 3.0% (151/5 039) of patients who received atezolizumab monotherapy. Of
these patients, three experienced fatal events. The median time to onset was 3.7 months (range: 3 days
to 29.8 months). The median duration was 1.7 months (range: 0 days to 27.8+ months; + denotes a
censored value). Pneumonitis led to discontinuation of atezolizumab in 41 (0.8%) patients.
Pneumonitis requiring the use of corticosteroids occurred in 1.8% (92/5 039) of patients receiving
atezolizumab monotherapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 2b7c254f2a9c366a260c823bbbe45a7d90a5cd097f1bbff72a65f83b96387d75 · Zeichen 17110–17619 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 23
HOS-135680 · Präparat HOS-097762
Immune-mediated hepatitis
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 6c8e72f0a856e72472f0d9263be6989af237421f38ce978a4fdeda8879f0411d · Zeichen 17621–17646 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 23
HOS-135681 · Präparat HOS-097762
Hepatitis occurred in 1.7% (88/5 039) of patients who received atezolizumab monotherapy. Of the
88 patients, three experienced fatal events. The median time to onset was 1.4 months (range: 0 days to
26.3 months). The median duration was 1 month (range: 0 day to 52.1+ months; + denotes a censored
value). Hepatitis led to discontinuation of atezolizumab in 46 (0.9%) patients. Hepatitis requiring the
use of corticosteroids occurred in 2.6% (130/5 039) of patients receiving atezolizumab monotherapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 62a3e35891b2d7050f756e6d3f9de7ccbbe53ecfd1374c87d520760e26df5e1d · Zeichen 17648–18148 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 23–24
HOS-135682 · Präparat HOS-097762
23
Immune-mediated colitis
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage dc769af314978d6e34c6d37d0776fe6d90d9381305527884640ee725eb00330b · Zeichen 18206–18233 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-135683 · Präparat HOS-097762
Colitis occurred in 1.2% (62/5 039) of patients who received atezolizumab monotherapy. The median
time to onset was 4.5 months (range: 15 days to 36.4 months). The median duration was 1.4 months
(range: 3 days to 50.2+ months; + denotes a censored value). Colitis led to discontinuation of
atezolizumab in 24 (0.5%) patients. Colitis requiring the use of corticosteroids occurred in 0.6%
(30/5 039) of patients receiving atezolizumab monotherapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 490c7b22d7ced45a735d55a8939c8cd6c169b1a6e8b1be8206f77507614d8579 · Zeichen 18235–18681 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-135684 · Präparat HOS-097762
Immune-mediated endocrinopathies
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage a21172ddf3823f362fe5cbd1e46966d87cbab6922f9ea689bfe5b4da67c8d2b6 · Zeichen 18683–18715 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-135685 · Präparat HOS-097762
Thyroid disorders
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 76dcbfd1774274ad1cb94dc7fed1530a9dc3a7066a34044be14d232af452f417 · Zeichen 18717–18734 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-135686 · Präparat HOS-097762
Hypothyroidism occurred in 8.5% (427/5 039) of patients who received atezolizumab monotherapy.
The median time to onset was 4.2 months (range: 0 days to 38.5 months). Hypothyroidism occurred in
17.4% (86/495) of patients who received atezolizumab monotherapy in the adjuvant NSCLC setting.
The median time to onset was 4.0 months (range: 22 days to 11.8 months).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 0e2a3fbb6d11ed4d8c062526ce000e325e2936e5086f1cc96e5c9fa85da267de · Zeichen 18736–19098 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-135687 · Präparat HOS-097762
Hyperthyroidism occurred in 2.4% (121/5 039) of patients who received atezolizumab monotherapy.
The median time to onset was 2.7 months (range: 0 days to 24.3 months). Hyperthyroidism occurred
in 6.5% (32/495) of patients who received atezolizumab monotherapy in the adjuvant NSCLC setting.
The median time to onset was 2.8 months (range: 1 day to 9.9 months).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 7e195d4c593d29ee5696ccdc896b441e4c52e01423143a67c24dbf093bf3c681 · Zeichen 19100–19460 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-135688 · Präparat HOS-097762
Adrenal insufficiency
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 826700287f9d1848d9dc1d70c141adeeddd597bb32c35ba103faef943f88d408 · Zeichen 19462–19483 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-135689 · Präparat HOS-097762
Adrenal insufficiency occurred in 0.5% (25/5 039) of patients who received atezolizumab
monotherapy. The median time to onset was 6.2 months (range: 3 days to 21.4 months). Adrenal
insufficiency led to discontinuation of atezolizumab in 5 (0.1%) patients. Adrenal insufficiency
requiring the use of corticosteroids occurred in 0.4% (20/5 039) of patients receiving atezolizumab
monotherapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 3595ae3bd6084205b06ee24abc3f0fe4cf9f6eb8b029b8725104aca8a3ebf2e8 · Zeichen 19485–19875 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-135690 · Präparat HOS-097762
Hypophysitis
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 61e4c475269ead21499f298e21d8889e23a45cb4295aa949324109dd542f328c · Zeichen 19877–19889 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-135691 · Präparat HOS-097762
Hypophysitis occurred in 0.2% (9/5 039) of patients who received atezolizumab monotherapy. The
median time to onset was 5.3 months (range: 21 days to 13.7 months). Six (0.1%) patients required the
use of corticosteroids and treatment with atezolizumab was discontinued in 1 (< 0.1%) patient.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 40e4c5af18200ff0ff39111b4c16d98c3f9c5c2ae4943f2aee69119a62f7e20a · Zeichen 19891–20182 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-135692 · Präparat HOS-097762
Hypophysitis occurred in 1.4% (15/1 093) of patients who received atezolizumab in combination with
paclitaxel followed by atezolizumab, dose-dense doxorubicin or epirubicin, and cyclophosphamide.
The median time to onset was 3.8 months (range: 2.4 to 10.7 months). Eleven patients (1.0%) required
the use of corticosteroids. Treatment with atezolizumab was discontinued in 7 (0.6%) patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 87b640654590f26d81b8602b083e88dab6ee0836a477b4be7587a87de7b5c8d6 · Zeichen 20184–20575 im Abschnitt
Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-135693 · Präparat HOS-097762
Hypophysitis occurred in 0.8% (3/393) of patients who received atezolizumab with bevacizumab,
paclitaxel, and carboplatin. The median time to onset was 7.7 months (range: 5.0 to 8.8 months). Two
patients required the use of corticosteroids.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage d3a5741b965a2b8d6d388022347679eed3659d98f21546fab8208178bc00862b · Zeichen 20577–20817 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.